Skip to main content
Top
Published in: Endocrine 1/2015

01-05-2015 | Endocrine Genetics/Epigenetics

Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region

Authors: Silvia Sambugaro, Mauro Di Ruvo, Maria Rosaria Ambrosio, Natalia S. Pellegata, Mariaenrica Bellio, Alessandra Guerra, Mattia Buratto, Maria Pia Foschini, Federico Tagliati, Ettore degli Uberti, Maria Chiara Zatelli

Published in: Endocrine | Issue 1/2015

Login to get access

Abstract

Genetic alterations frequently are involved in the development of a pituitary adenoma in young age. We here characterize the functional role of a deletion in CDKN1B 5′-UTR region (c.-29_-26delAGAG) identified in an acromegalic patient that developed a growth hormone in pituitary adenoma during childhood. Our results show that the identified novel heterozygous deletion in the CDKN1B 5′-UTR region associates with a reduction in CDKN1B mRNA levels, a predicted altered secondary mRNA structure, and a reduced CDKN1B 5′-UTR transcriptional activity in vitro. The patient displayed loss of heterozygosity in the same CDKN1B 5′-UTR region at tissue level and the 5′UTR region containing the deleted sequence encompasses a GRE. These findings indicate that the identification of functional alterations of newly discovered genetic derangements need to be fully characterized and always correlated with the clinical manifestations.
Appendix
Available only for authorised users
Literature
1.
go back to reference A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRefPubMed A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRefPubMed
2.
go back to reference A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72, 377–382 (2010)CrossRef A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72, 377–382 (2010)CrossRef
3.
go back to reference N.S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, M.J. Atkinson, Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. 103, 15558–15563 (2006)CrossRefPubMedCentralPubMed N.S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, M.J. Atkinson, Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. 103, 15558–15563 (2006)CrossRefPubMedCentralPubMed
4.
go back to reference M. Lee, N.S. Pellegata, Multiple endocrine neoplasia syndromes associated with mutation of p27. J. Endocrinol. Invest. 36(9), 781–787 (2013)PubMed M. Lee, N.S. Pellegata, Multiple endocrine neoplasia syndromes associated with mutation of p27. J. Endocrinol. Invest. 36(9), 781–787 (2013)PubMed
5.
go back to reference M.A. Tichomirowa, M. Lee, A. Barlier, A.F. Daly, I. Marinoni, M.L. Jaffrain-Rea, L.A. Naves, P. Rodien, V. Rohmer, F.R. Faucz, P. Caron, B. Estour, P. Lecomte, F. Borson-Chazot, A. Penfornis, M. Yaneva, M. Guitelman, E. Castermans, C. Verhaege, J.L. Wémeau, A. Tabarin, C. Fajardo Montañana, B. Delemer, V. Kerlan, J.L. Sadoul, C. Cortet Rudelli, F. Archambeaud, S. Zacharieva, M. Theodoropoulou, T. Brue, A. Enjalbert, V. Bours, N.S. Pellegata, A. Beckers, Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr. Relat. Cancer 19(3), 233–241 (2012)CrossRefPubMed M.A. Tichomirowa, M. Lee, A. Barlier, A.F. Daly, I. Marinoni, M.L. Jaffrain-Rea, L.A. Naves, P. Rodien, V. Rohmer, F.R. Faucz, P. Caron, B. Estour, P. Lecomte, F. Borson-Chazot, A. Penfornis, M. Yaneva, M. Guitelman, E. Castermans, C. Verhaege, J.L. Wémeau, A. Tabarin, C. Fajardo Montañana, B. Delemer, V. Kerlan, J.L. Sadoul, C. Cortet Rudelli, F. Archambeaud, S. Zacharieva, M. Theodoropoulou, T. Brue, A. Enjalbert, V. Bours, N.S. Pellegata, A. Beckers, Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr. Relat. Cancer 19(3), 233–241 (2012)CrossRefPubMed
6.
go back to reference G. Occhi, G. Trivellin, F. Ceccato, P. De Lazzari, G. Giorgi, S. Demattè, F. Grimaldi, R. Castello, M.V. Davì, G. Arnaldi, L. Salviati, G. Opocher, F. Mantero, C. Scaroni, Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 163(3), 369–376 (2010)CrossRefPubMed G. Occhi, G. Trivellin, F. Ceccato, P. De Lazzari, G. Giorgi, S. Demattè, F. Grimaldi, R. Castello, M.V. Davì, G. Arnaldi, L. Salviati, G. Opocher, F. Mantero, C. Scaroni, Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 163(3), 369–376 (2010)CrossRefPubMed
8.
go back to reference S.K. Agarwal, C.M. Mateo, S.J. Marx, Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826–1834 (2009)CrossRefPubMedCentralPubMed S.K. Agarwal, C.M. Mateo, S.J. Marx, Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826–1834 (2009)CrossRefPubMedCentralPubMed
9.
go back to reference G. Occhi, D. Regazzo, G. Trivellin, F. Boaretto, D. Ciato, S. Bobisse, S. Ferasin, F. Cetani, E. Pardi, M. Korbonits, N.S. Pellegata, V. Sidarovich, A. Quattrone, G. Opocher, F. Mantero, C. Scaroni, A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 9(3), E1003350 (2013)CrossRefPubMedCentralPubMed G. Occhi, D. Regazzo, G. Trivellin, F. Boaretto, D. Ciato, S. Bobisse, S. Ferasin, F. Cetani, E. Pardi, M. Korbonits, N.S. Pellegata, V. Sidarovich, A. Quattrone, G. Opocher, F. Mantero, C. Scaroni, A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 9(3), E1003350 (2013)CrossRefPubMedCentralPubMed
10.
go back to reference M. Georgitsi, A. Raitila, A. Karhu, R.B. van der Luijt, C.M. Aalfs, T. Sane et al., Germline cdkn1b/p27kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92(8), 3321–3355 (2007)CrossRefPubMed M. Georgitsi, A. Raitila, A. Karhu, R.B. van der Luijt, C.M. Aalfs, T. Sane et al., Germline cdkn1b/p27kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92(8), 3321–3355 (2007)CrossRefPubMed
11.
go back to reference S. Molatore, I. Marinoni, M. Lee, E. Pulz, M.R. Ambrosio et al., A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum. Mutat. 31, E1825–E1835 (2010)CrossRefPubMedCentralPubMed S. Molatore, I. Marinoni, M. Lee, E. Pulz, M.R. Ambrosio et al., A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum. Mutat. 31, E1825–E1835 (2010)CrossRefPubMedCentralPubMed
12.
go back to reference S. Takeuchi, H.P. Koeffler, D.R. Hinton, I. Miyoshi, S. Melmed, I. Shimon, Mutation and expression analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J. Endocrinol. 157, 337–341 (1998)CrossRefPubMed S. Takeuchi, H.P. Koeffler, D.R. Hinton, I. Miyoshi, S. Melmed, I. Shimon, Mutation and expression analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J. Endocrinol. 157, 337–341 (1998)CrossRefPubMed
13.
go back to reference D. Malanga, S. De Gisi, M. Riccardi, M. Scrima, C. De Marco, M. Robledo, G. Viglietto, Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur. J. Endocrinol. 166, 551–560 (2012)CrossRefPubMed D. Malanga, S. De Gisi, M. Riccardi, M. Scrima, C. De Marco, M. Robledo, G. Viglietto, Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur. J. Endocrinol. 166, 551–560 (2012)CrossRefPubMed
14.
go back to reference M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467–473 (2009)CrossRefPubMed M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467–473 (2009)CrossRefPubMed
15.
go back to reference F. Tagliati, E. Gentilin, M. Buratto, D. Molè, E.C. degli Uberti, M.C. Zatelli, Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 151(10), 4635–4642 (2010)CrossRefPubMed F. Tagliati, E. Gentilin, M. Buratto, D. Molè, E.C. degli Uberti, M.C. Zatelli, Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 151(10), 4635–4642 (2010)CrossRefPubMed
16.
go back to reference M.C. Zatelli, M. Minoia, D. Molè, V. Cason, F. Tagliati, A. Margutti, M. Bondanelli, M.R. Ambrosio, E. degli Uberti, Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab. 94(10), 3931–3938 (2009)CrossRefPubMed M.C. Zatelli, M. Minoia, D. Molè, V. Cason, F. Tagliati, A. Margutti, M. Bondanelli, M.R. Ambrosio, E. degli Uberti, Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab. 94(10), 3931–3938 (2009)CrossRefPubMed
17.
go back to reference L. Hengst, S.I. Reed, Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996)CrossRefPubMed L. Hengst, S.I. Reed, Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996)CrossRefPubMed
18.
go back to reference M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P.R. Yew, G.F. Draetta, M. Rolfe, Role of the ubiquitin—proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 269, 682–685 (1995)CrossRefPubMed M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P.R. Yew, G.F. Draetta, M. Rolfe, Role of the ubiquitin—proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 269, 682–685 (1995)CrossRefPubMed
19.
go back to reference G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, M.L. Motti, R. Pasquinelli, V. Agosti, M. Robledo, A. Fusco, G. Viglietto, Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr. Relat. Cancer 14, 405–420 (2007)CrossRefPubMed G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, M.L. Motti, R. Pasquinelli, V. Agosti, M. Robledo, A. Fusco, G. Viglietto, Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr. Relat. Cancer 14, 405–420 (2007)CrossRefPubMed
20.
go back to reference A. Peiretti, N. Baghdassarian, L.M. Gerland, P. Ffrench, P.A. Bryon, J.P. Magaud et al., CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes. Eur. J. Cell Biol. 82, 253–261 (2003)CrossRefPubMed A. Peiretti, N. Baghdassarian, L.M. Gerland, P. Ffrench, P.A. Bryon, J.P. Magaud et al., CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes. Eur. J. Cell Biol. 82, 253–261 (2003)CrossRefPubMed
21.
go back to reference J. Slingerland, M. Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183(1), 10–17 (2000)CrossRefPubMed J. Slingerland, M. Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183(1), 10–17 (2000)CrossRefPubMed
22.
go back to reference M.K. Kullmann, C. Grubbauer, K. Goetsch, H. Jäkel, S.R. Podmirseg, A. Trockenbacher, C. Ploner, A.C. Cato, C. Weiss, R. Kofler, L. Hengst, The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 12(16), 2625–2635 (2013)CrossRefPubMedCentralPubMed M.K. Kullmann, C. Grubbauer, K. Goetsch, H. Jäkel, S.R. Podmirseg, A. Trockenbacher, C. Ploner, A.C. Cato, C. Weiss, R. Kofler, L. Hengst, The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 12(16), 2625–2635 (2013)CrossRefPubMedCentralPubMed
Metadata
Title
Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region
Authors
Silvia Sambugaro
Mauro Di Ruvo
Maria Rosaria Ambrosio
Natalia S. Pellegata
Mariaenrica Bellio
Alessandra Guerra
Mattia Buratto
Maria Pia Foschini
Federico Tagliati
Ettore degli Uberti
Maria Chiara Zatelli
Publication date
01-05-2015
Publisher
Springer US
Published in
Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0540-y

Other articles of this Issue 1/2015

Endocrine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine